Merck, Baylor College to Advance Manufacturing Platform for Covid-19 Vaccine Candidates
May 27 2020 - 10:28AM
Dow Jones News
By Giulia Petroni
Merck KGaA said Wednesday that it has extended its collaboration
with Baylor College of Medicine in Houston to accelerate
manufacturing of Baylor's Covid-19 vaccine candidates.
The German pharmaceuticals and chemicals company said the teams
will improve the manufacturing platform for the CoV RBD219-N1
vaccine candidate and develop a new manufacturing platform for a
second candidate to accelerate the transition to phase-1 clinical
trials.
"The goal for the partnership is to develop a manufacturing
process and steps that would lead to a scale-up approach suitable
for pilot and later industrial production," it said.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
May 27, 2020 10:13 ET (14:13 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Mar 2023 to Mar 2024